Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVEONASDAQ:IFRXNASDAQ:SESNNASDAQ:TFFPNASDAQ:TRVI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsIFRXInflaRx$1.36$1.54$1.14▼$5.20$80.08M1.27235,815 shs1,005 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsTFFPTFF Pharmaceuticals$3.01+1.3%$6.02$2.51▼$21.25$7.59M1.2937,849 shs12,712 shsTRVITrevi Therapeutics$2.59-2.3%$3.00$0.97▼$4.00$178.61M0.86276,928 shs4,510 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IFRXInflaRx0.00%+7.51%-11.69%-9.33%-71.06%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%TFFPTFF Pharmaceuticals-0.50%-7.11%-59.32%-40.63%-78.11%TRVITrevi Therapeutics-7.02%+2.71%-20.90%+99.25%-9.56%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIFRXInflaRx2.1999 of 5 stars3.83.00.00.00.01.71.3SESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals1.1535 of 5 stars3.53.00.00.00.60.00.6TRVITrevi Therapeutics2.495 of 5 stars3.54.00.00.01.43.30.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO PharmaceuticalsN/AN/AN/AN/AIFRXInflaRx3.50Strong Buy$13.50892.65% UpsideSESNSesen BioN/AN/AN/AN/ATFFPTFF Pharmaceuticals3.00Buy$72.002,292.03% UpsideTRVITrevi Therapeutics3.00Buy$8.50228.19% UpsideCurrent Analyst RatingsLatest AVEO, SESN, IFRX, TRVI, and TFFP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/28/2024TFFPTFF PharmaceuticalsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $44.003/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/21/2024TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/21/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.001/25/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28IFRXInflaRx$70K1,143.95N/AN/A$1.89 per share0.72SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00TFFPTFF Pharmaceuticals$730K10.39N/AN/A$4.04 per share0.75TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/AIFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)SESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ATFFPTFF Pharmaceuticals-$21.24M-$12.51N/AN/AN/A-2,897.95%-163.14%-144.77%5/9/2024 (Estimated)TRVITrevi Therapeutics-$29.07M-$0.29N/AN/AN/AN/A-31.51%-28.89%5/9/2024 (Estimated)Latest AVEO, SESN, IFRX, TRVI, and TFFP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023TFFPTFF Pharmaceuticals-$2.00-$2.01-$0.01-$2.01$0.20 million$0.11 million3/21/2024Q4 2023IFRXInflaRx-$0.20-$0.30-$0.10-$0.30N/AN/A3/20/2024Q4 2023TRVITrevi Therapeutics-$0.10-$0.08+$0.02-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35IFRXInflaRxN/A6.505.82SESNSesen BioN/A6.106.10TFFPTFF PharmaceuticalsN/A3.123.12TRVITrevi TherapeuticsN/A15.0315.03OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%IFRXInflaRx42.39%SESNSesen Bio16.45%TFFPTFF Pharmaceuticals15.25%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%IFRXInflaRx16.30%SESNSesen Bio3.20%TFFPTFF Pharmaceuticals5.60%TRVITrevi Therapeutics27.46%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableIFRXInflaRx6258.88 million49.29 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableTFFPTFF Pharmaceuticals192.52 million2.38 millionOptionableTRVITrevi Therapeutics2568.96 million50.02 millionOptionableAVEO, SESN, IFRX, TRVI, and TFFP HeadlinesSourceHeadlineCritical Analysis: Pliant Therapeutics (NASDAQ:PLRX) vs. Trevi Therapeutics (NASDAQ:TRVI)americanbankingnews.com - April 20 at 2:16 AMTrevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Nowzacks.com - April 18 at 10:56 AMTwo stand-ups to perform at Trevi this Saturdaysaultstar.com - April 17 at 7:02 PMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferencefinance.yahoo.com - April 9 at 9:54 AMTrevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from Needham & Company LLCmarketbeat.com - April 9 at 8:30 AMTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conferenceprnewswire.com - April 9 at 7:30 AMTrevi Therapeutics appoints new VP for clinical developmentuk.investing.com - April 4 at 7:56 PMWhy Trevi Therapeutics (TRVI) Stock Might be a Great Pickzacks.com - April 4 at 9:31 AMTrevi Therapeutics to Participate in Upcoming April Eventsprnewswire.com - April 4 at 7:30 AMTrevi piles into Melbourne’s Link megaproject with four hyrdromillsglobalconstructionreview.com - April 3 at 10:24 AMCity worker cleans coins at Trevi Fountain in Romechinaview.cn - April 2 at 8:36 PMTrevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Teamfinance.yahoo.com - April 2 at 10:35 AMTourists throw over €1 million into Italy’s Trevi Fountain each year. Here’s what happens to itmsn.com - March 29 at 7:12 PMTrevi Italian Restaurant at Forum Shops unexpectedly closesmsn.com - March 28 at 9:44 PMProminent Trevi Italian Restaurant Abruptly Closes at the Forum Shopsmsn.com - March 27 at 1:26 PMTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcriptinsidermonkey.com - March 21 at 11:14 AMTrevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - March 21 at 7:22 AMTrevi Therapeutics: Q4 Earnings Insightsbenzinga.com - March 20 at 9:21 PMTRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023msn.com - March 20 at 9:21 PMTrevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trialsfinance.yahoo.com - March 20 at 9:21 PMGloria Trevi Lights Up New York, Debuts ‘Zorra' Remix With Nebulossamsn.com - March 17 at 10:44 PMGloria Trevi Lights Up New York, Debuts ‘Zorra’ Remix With Nebulossamsn.com - March 16 at 4:38 PMWhat happens to the coins tossed into Rome's Trevi Fountain?astroawani.com - March 15 at 11:04 PMTrevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024finance.yahoo.com - March 13 at 8:28 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAVEO PharmaceuticalsNASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Sesen BioNASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.TFF PharmaceuticalsNASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.Trevi TherapeuticsNASDAQ:TRVITrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.